The Roles of Non-Pharmacologic and Emerging Pharmacologic Management of Non-alcoholic Fatty Liver Disease and Sarcopenia: A Narrative Review
- PMID: 38863907
- PMCID: PMC11163315
- DOI: 10.15605/jafes.039.01.04
The Roles of Non-Pharmacologic and Emerging Pharmacologic Management of Non-alcoholic Fatty Liver Disease and Sarcopenia: A Narrative Review
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent causes of chronic liver disease worldwide which is often seen in patients with metabolic abnormalities such as those with obesity and insulin resistance. On the other hand, sarcopenia is a generalized and progressive skeletal muscle disorder characterized by low muscle strength, low muscle quality, low physical performance, or a combination of the three. Both disease entities share several underlying risk factors and pathophysiologic mechanisms. These include: (1) cardiometabolic overlaps such as insulin resistance, chronic systemic inflammation, decreased vitamin D levels, sex hormone modifications; (2) muscle-related factors such as those mitigated by myostatin signaling, and myokines (i.e., irisin); and (3) liver-dysfunction related factors such as those associated with growth hormone/insulin-like growth factor 1 Axis, hepatokines (i.e., selenoprotein P and leukocyte cell-derived chemotaxin-2), fibroblast growth factors 21 and 19 (FGF21 and FGF19), and hyperammonemia. This narrative review will examine the pathophysiologic overlaps that can explain the links between NAFLD and sarcopenia. Furthermore, this review will explore the emerging roles of nonpharmacologic (e.g., weight reduction, diet, alcohol, and smoking cessation, and physical activity) and pharmacologic management (e.g., roles of β-hydroxy-β-methylbutyrate, branched-chain amino acid supplements, and testosterone therapy) to improve care, intervention sustainability, and acceptability for patients with sarcopenia-associated NAFLD.
Keywords: NAFLD; fatty liver disease; sarcopenia.
© 2024 Journal of the ASEAN Federation of Endocrine Societies.
Conflict of interest statement
The authors declared no conflict of interest.
Figures

Similar articles
-
Sarcopenia and fatty liver disease.Hepatol Int. 2019 Nov;13(6):674-687. doi: 10.1007/s12072-019-09996-7. Epub 2019 Nov 8. Hepatol Int. 2019. PMID: 31705444 Review.
-
Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk.Ageing Res Rev. 2022 Sep;80:101696. doi: 10.1016/j.arr.2022.101696. Epub 2022 Jul 14. Ageing Res Rev. 2022. PMID: 35843589 Review.
-
Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?Can J Gastroenterol Hepatol. 2020 Oct 31;2020:8859719. doi: 10.1155/2020/8859719. eCollection 2020. Can J Gastroenterol Hepatol. 2020. PMID: 33204675 Free PMC article. Review.
-
The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.Front Endocrinol (Lausanne). 2021 Nov 10;12:716533. doi: 10.3389/fendo.2021.716533. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34858322 Free PMC article. Review.
-
Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.Dig Dis Sci. 2016 Nov;61(11):3190-3198. doi: 10.1007/s10620-016-4285-0. Epub 2016 Aug 29. Dig Dis Sci. 2016. PMID: 27572941
Cited by
-
Cardiometabolic Index is associated with heart failure: a cross-sectional study based on NHANES.Front Med (Lausanne). 2024 Dec 9;11:1507100. doi: 10.3389/fmed.2024.1507100. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39717172 Free PMC article.
-
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia.Int J Mol Sci. 2025 May 14;26(10):4673. doi: 10.3390/ijms26104673. Int J Mol Sci. 2025. PMID: 40429815 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical